Literature DB >> 19687736

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Saila P Kauhanen1, Gaber Komar, Marko P Seppänen, Kirsti I Dean, Heikki R Minn, Sami A Kajander, Irina Rinta-Kiikka, Kalle Alanen, Ronald J Borra, Pauli A Puolakkainen, Pirjo Nuutila, Jari T Ovaska.   

Abstract

OBJECTIVE: To prospectively compare the accuracy of combined positron emission tomography/computed tomography using F-fluorodeoxyglucose (FDG-PET/CT), multidetector row computed tomography (MDCT), and magnetic resonance imaging (MRI) in the evaluation of patients with suspected pancreatic malignancy. SUMMARY BACKGROUND DATA: FDG-PET/CT imaging is increasingly used for staging of pancreatic cancer. Preliminary data suggest a significant influence of FDG-PET/CT on treatment planning, although its role is still evolving.
METHODS: Thirty-eight consecutive patients with suspicion of pancreatic malignancy were enrolled. Patients underwent a protocol including FDG-PET/CT, MDCT, and MRI combined with magnetic resonance cholangiopancreatography, all of which were blindly evaluated. The findings were confirmed macroscopically at operation and/or by histopathologic analysis (n = 29) or follow-up (n = 9). Results of TNM classification of different imaging methods were compared with clinical TNM classification.
RESULTS: Pancreatic adenocarcinoma was diagnosed in 17 patients, neuroendocrine tumor in 3, mass-forming pancreatitis in 4, cystic lesion in 6, and fibrosis in 2. Six patients had a finding of a normal pancreas. The diagnostic accuracy of FDG-PET/CT for pancreatic malignancy was 89%, compared with 76% and 79% for MDCT and MRI, respectively. In the differential diagnosis of suspected malignant biliary stricture at endoscopic retrograde cholangiopancreaticography (n = 21), FDG-PET/CT had a positive predictive value of 92%. In 17 patients with advanced pancreatic adenocarcinoma, FDG-PET/CT had a sensitivity of 30% for N- and 88% for M-staging. Both MDCT and MRI had sensitivities of 30% for N- and 38% for M-staging. Furthermore, the clinical management of 10 patients (26%) was altered after FDG-PET/CT.
CONCLUSION: FDG-PET/CT was more sensitive than conventional imaging in the diagnosis of both primary pancreatic adenocarcinoma and associated distant metastases. In contrast, the sensitivity of FDG-PET/CT was poor in detecting local lymph node metastasis, which would have been important for an assessment of resectability. We recommend the use of FDG-PET/CT in the evaluation of diagnostically challenging cases, especially in patients with biliary strictures without evidence of malignancy in conventional imaging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687736     DOI: 10.1097/SLA.0b013e3181b2fafa

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  77 in total

1.  The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.

Authors:  Woohyun Jung; Jin-Young Jang; Mee Joo Kang; Ye Rim Chang; Yong Chan Shin; Jihoon Chang; Sun-Whe Kim
Journal:  HPB (Oxford)       Date:  2015-12-21       Impact factor: 3.647

2.  Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.

Authors:  Nerissa Therese Viola-Villegas; Samuel L Rice; Sean Carlin; Xiaohong Wu; Michael J Evans; Kuntal K Sevak; Marija Drobjnak; Govind Ragupathi; Ritsuko Sawada; Wolfgang W Scholz; Philip O Livingston; Jason S Lewis
Journal:  J Nucl Med       Date:  2013-09-12       Impact factor: 10.057

3.  Pancreato-biliary malignancy diagnosed by endoscopic ultrasonography in absence of a mass lesion on transabdominal imaging: prevalence and predictors.

Authors:  Savio C Reddymasu; Neil Gupta; Shailender Singh; Melissa Oropeza-Vail; Syed Faisal Jafri; Mojtaba Olyaee
Journal:  Dig Dis Sci       Date:  2010-12-28       Impact factor: 3.199

Review 4.  Current treatment options for pancreatic carcinoma.

Authors:  Emily Castellanos; Jordan Berlin; Dana Backlund Cardin
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

5.  FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.

Authors:  Zhen Wang; Jun-Qiang Chen; Jin-Lu Liu; Xin-Gan Qin; Yuan Huang
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

6.  Intraoperative ultrasound with contrast medium in resective pancreatic surgery: a pilot study.

Authors:  Antonino Spinelli; Daniele Del Fabbro; Matteo Sacchi; Alessandro Zerbi; Guido Torzilli; Fabio R Lutman; Luigi Laghi; Alberto Malesci; Marco Montorsi
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

Review 7.  Pancreatic involvement by plasma cell neoplasms.

Authors:  Rodrigo Lopes da Silva
Journal:  J Gastrointest Cancer       Date:  2012-06

Review 8.  Pancreatic neoplasia: a practical cross-sectional imaging primer for the nonradiologist.

Authors:  Matthew T Heller; Nathan Johnson; Antonio Fargiano
Journal:  J Gastrointest Cancer       Date:  2012-06

9.  Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility?

Authors:  Sam G Pappas; Kathleen K Christians; Parag P Tolat; Alan P Mautz; Alysandra Lal; Lisa McElroy; T Clark Gamblin; Kiran K Turaga; Susan Tsai; Beth Erickson; Paul Ritch; Douglas B Evans
Journal:  HPB (Oxford)       Date:  2013-03-15       Impact factor: 3.647

10.  Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle.

Authors:  Shaunagh McDermott; Sarah P Thayer; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Ralph Weissleder; Mukesh G Harisinghani
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.